Epstein E
Arch Dermatol. 1985 Feb;121(2):207-13.
Treatment of thin (superficial) basal cell carcinomas (BCCs) with topical fluorouracil is widely accepted despite the absence of published five-year cure rates. The published short-term data disclose treatment failure rates substantially higher than other modalities. In trials to improve and standardize topical fluorouracil therapy, thin BCCs were treated with 25% fluorouracil in petrolatum under occlusion for three weeks using weekly dressing changes. Of 44 thin BCCs treated only with 25% fluorouracil under occlusion for three weeks, the five-year cumulative recurrence rate was 21%. In a second series of 244 BCCs, light curettage preceded the 25% fluorouracil treatment to yield a five-year cumulative recurrence rate of 6%. Cosmetic results were good to excellent in more than 80% of both series. While fluorouracil by itself is not a satisfactory treatment for thin BCC, when combined with light curettage, topical fluorouracil therapy is capable of cure rates competitive with other modalities.
尽管缺乏已发表的五年治愈率数据，但外用氟尿嘧啶治疗薄型（浅表型）基底细胞癌（BCC）已被广泛接受。已发表的短期数据显示，其治疗失败率远高于其他治疗方式。在旨在改进和规范外用氟尿嘧啶治疗的试验中，薄型基底细胞癌患者使用含25%氟尿嘧啶的凡士林封闭治疗三周，每周更换敷料。在仅接受25%氟尿嘧啶封闭治疗三周的44例薄型基底细胞癌患者中，五年累积复发率为21%。在另一组244例基底细胞癌患者中，在25%氟尿嘧啶治疗前先进行轻度刮除术，五年累积复发率为6%。两个系列中超过80%的患者美容效果良好至极佳。虽然氟尿嘧啶本身对薄型基底细胞癌并非令人满意的治疗方法，但与轻度刮除术联合使用时，外用氟尿嘧啶治疗的治愈率可与其他治疗方式相媲美。
